The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation

[1]  H. Baba,et al.  Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers , 2020, British Journal of Cancer.

[2]  Y. Bang,et al.  Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study. , 2019, Journal of Clinical Oncology.

[3]  J. V. van Sandick,et al.  Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma. , 2019, Cancer letters.

[4]  M. Salto‐Tellez,et al.  Critical Appraisal of Programmed Death Ligand 1 Reflex Diagnostic Testing: Current Standards and Future Opportunities , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  M. Salto‐Tellez,et al.  Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer , 2018, Journal of oncology.

[6]  M. Salto‐Tellez,et al.  Sex hormone receptor expression and survival in esophageal adenocarcinoma: a prospective cohort study , 2018, Oncotarget.

[7]  K. Mills,et al.  The Northern Ireland Biobank: A Cancer Focused Repository of Science , 2018 .

[8]  M. Salto‐Tellez,et al.  Validation of the systematic scoring of immunohistochemically stained tumour tissue microarrays using QuPath digital image analysis , 2018, Histopathology.

[9]  M. Salto‐Tellez,et al.  Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma , 2018, Oncotarget.

[10]  J. Silverman,et al.  The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation , 2017, Annals of surgery.

[11]  Gerald Li,et al.  Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer , 2018, Laboratory Investigation.

[12]  Ying Sun,et al.  Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications , 2017, Theranostics.

[13]  Donavan T. Cheng,et al.  PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. , 2017, JCO precision oncology.

[14]  K. Schalper,et al.  Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis. , 2017, JCO precision oncology.

[15]  E. Jaffee,et al.  Targeting neoantigens to augment antitumour immunity , 2017, Nature Reviews Cancer.

[16]  Peter Bankhead,et al.  QuPath: Open source software for digital pathology image analysis , 2017, Scientific Reports.

[17]  A. Ochiai,et al.  Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein–Barr virus status in a large cohort of gastric cancer patients , 2017, Gastric Cancer.

[18]  M. Atkins,et al.  Predictive biomarkers for checkpoint inhibitor-based immunotherapy. , 2016, The Lancet. Oncology.

[19]  C. Perou,et al.  Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. , 2016, Journal of the National Cancer Institute.

[20]  Y. Shim,et al.  Prognostic Significance of PD‐L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  S. Nomura,et al.  Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma , 2016, Oncotarget.

[22]  J. Lunceford,et al.  Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. , 2016, The Lancet. Oncology.

[23]  W. Mao,et al.  Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma , 2016, Oncotarget.

[24]  A. Bateman,et al.  Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma , 2016, Cancer Immunology, Immunotherapy.

[25]  M. Zhong,et al.  The clinical impact of ICOS signal in colorectal cancer patients , 2016, Oncoimmunology.

[26]  Toby C. Cornish,et al.  Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma , 2016, Gut.

[27]  Jingting Jiang,et al.  B7-H1 expression associates with tumor invasion and predicts patient's survival in human esophageal cancer. , 2014, International journal of clinical and experimental pathology.

[28]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[29]  S. Ambs,et al.  Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry , 2013, Cancer Immunology, Immunotherapy.

[30]  E W Steyerberg,et al.  Preoperative chemoradiotherapy for esophageal or junctional cancer. , 2012, The New England journal of medicine.

[31]  G. Murray,et al.  The expression profile of RNA-binding proteins in primary and metastatic colorectal cancer: relationship of heterogeneous nuclear ribonucleoproteins with prognosis. , 2011, Human pathology.

[32]  W. Chow,et al.  Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. , 2008, Journal of the National Cancer Institute.

[33]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[34]  J. Cheville,et al.  B7-H4 expression in renal cell carcinoma and tumor vasculature: Associations with cancer progression and survival , 2006, Proceedings of the National Academy of Sciences.

[35]  A. Harris,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British Journal of Cancer.

[36]  D G Altman,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British journal of cancer.

[37]  M. Azuma,et al.  Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer , 2005, Clinical Cancer Research.

[38]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[39]  P. Schlag,et al.  Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. , 2001, Cancer research.